litlas
Log inCreate account

Maurie Markman

Active 1984–2019

93
Papers
22,787
Citations
83
h-index
93
i10-index

Citations

Citations per year for Maurie Markman1985: 5 citations1986: 11 citations1987: 6 citations1988: 8 citations1989: 11 citations1990: 4 citations1991: 9 citations1992: 15 citations1993: 26 citations1994: 16 citations1995: 16 citations1996: 24 citations1997: 21 citations1998: 40 citations1999: 37 citations2000: 41 citations2001: 61 citations2002: 70 citations2003: 102 citations2004: 97 citations2005: 118 citations2006: 135 citations2007: 149 citations2008: 136 citations2009: 167 citations2010: 145 citations2011: 152 citations2012: 161 citations2013: 110 citations2014: 204 citations2015: 472 citations2016: 320 citations2017: 187 citations2018: 131 citations2019: 570 citations2020: 425 citations2021: 322 citations2022: 259 citations2023: 134 citations2024: 196 citations2025: 73 citations2026: 2 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,986 citing papers, 30% of this breakdownChina: 808 citing papers, 12.2% of this breakdownUnited Kingdom: 346 citing papers, 5.2% of this breakdownItaly: 343 citing papers, 5.2% of this breakdownCanada: 249 citing papers, 3.8% of this breakdownGermany: 230 citing papers, 3.5% of this breakdownJapan: 210 citing papers, 3.2% of this breakdownFrance: 209 citing papers, 3.2% of this breakdownAustralia: 177 citing papers, 2.7% of this breakdownNetherlands: 176 citing papers, 2.7% of this breakdownSpain: 152 citing papers, 2.3% of this breakdownSouth Korea: 135 citing papers, 2% of this breakdown
0%30%Other 24%

Institutions

Fields

  • Medicine62.9%
  • Biochemistry, Genetics and Molecular Biology25.8%
  • Materials Science2.6%
  • Immunology and Microbiology2.5%
  • Computer Science0.8%
  • Economics, Econometrics and Finance0.8%
  • Other4.6%

Topics

  • Ovarian cancer diagnosis and treatment8.8%
  • Intraperitoneal and Appendiceal Malignancies4.4%
  • PARP inhibition in cancer therapy3.3%
  • Endometrial and Cervical Cancer Treatments2.4%
  • Cancer-related molecular mechanisms research1.8%
  • MicroRNA in disease regulation1.6%
  • Other77.7%

Coauthors

All papers

Open in search
  1. Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature

    Authors: Peter Y. Park, Teresa A. Goldin, John C. S. Chang, Maurie Markman, Madappa N. Kundranda - Case Reports in Oncology 2015 cited by 5,277

  2. Ovarian cancer

    Authors: Bryan T. Hennessy, Robert L. Coleman, Maurie Markman - The Lancet 2009 cited by 652

  3. Role of nutritional status in predicting quality of life outcomes in cancer – a systematic review of the epidemiological literature

    Authors: C. G. Lis, Digant Gupta, C. A. Lammersfeld, Maurie Markman, Pankaj G. Vashi - Nutrition Journal 2012 cited by 312

  4. Paclitaxel in cancer therapy

    Authors: Maurie Markman, Tarek Mekhail - Expert Opinion on Pharmacotherapy 2002 cited by 379

  5. Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

    Authors: Maurie Markman, Brian N. Bundy, David S. Alberts, Jeffrey M. Fowler, D L Clark-Pearson, Linda F. Carson, Scott Wadler, Joshua Z. Sickel - Journal of Clinical Oncology 2001 cited by 1,088

  6. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

    Authors: Maurie Markman, Robert Rothman, Thomas B. Hakes, Bonnie Reichman, William J. Hoskins, Stephen C. Rubin, Wanda K. Jones, Lois Almadrones, John L. Lewis - Journal of Clinical Oncology 1991 cited by 854

  7. Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    Authors: William E. Winter, G. Larry Maxwell, Chunqiao Tian, Jay W. Carlson, Robert F. Ozols, Peter G. Rose, Maurie Markman, Deborah K. Armstrong, Franco M. Muggia, William P. McGuire - Journal of Clinical Oncology 2007 cited by 846

  8. Clinical Features of Hypersensitivity Reactions to Carboplatin

    Authors: Maurie Markman, Alexander Kennedy, Kenneth Webster, Paul Elson, Gertrude Peterson, Barbara Kulp, Jerome L. Belinson - Journal of Clinical Oncology 1999 cited by 374

  9. Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

    Authors: Bryan T. Hennessy, Kirsten M. Timms, Mark Carey, Alexander Gutin, Larissa A. Meyer, Darl D. Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn, Yang Li, Jie Li, Ana M. González-Angulo, Karen McCune, Maurie Markman, Russell R. Broaddus, Jerry S. Lanchbury, Karen H. Lu, Gordon B. Mills - Journal of Clinical Oncology 2010 cited by 373

  10. Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

    Authors: Devansu Tewari, James Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, John K. Chan - Journal of Clinical Oncology 2015 cited by 286

  11. Intraperitoneal antineoplastic drug delivery: rationale and results

    Authors: Maurie Markman - The Lancet Oncology 2003 cited by 236

  12. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery

    Authors: Arancha Prada-Villaverde, Jesús Esquivel, Andrew M. Lowy, Maurie Markman, Terence C. Chua, Joerg Pelz, Dario Baratti, Joel Baumgartner, Richard Berri, Pedro Bretcha-Boix, Marcello Deraco, Guillermo Flores-Ayala, Olivier Gléhen, Alberto Gómez-Portilla, Santiago González‐Moreno, Martin Goodman, Evgenia Halkia, Shigeki Kusamura, Mecker G. Möller, Guillaume Passot, Marc Pocard, George I. Salti, Armando Sardi, Maheswari Senthil, John Spiliotis, Juan Torres-Melero, Kiran K. Turaga, Richard Trout - Journal of Surgical Oncology 2014 cited by 161

  13. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

    Authors: David S. Alberts, Christian Marth, Ronald D. Alvarez, Gary A. Johnson, Mariusz Bidziński, David Kardatzke, Williamson Z. Bradford, Jeff Loutit, David H. Kirn, Mary C. Clouser, Maurie Markman - Gynecologic Oncology 2008 cited by 129

  14. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000

    Authors: Patricia J. Eifel, Jan Axelson, Janitha Costa, John Crowley, W.J. Curran, Amy M.B. Deshler, Sarah Fulton, Carolyn B. Hendricks, Margaret Kemeny, Alice B. Kornblith, Thomas A. Louis, Maurie Markman, Robert J. Mayer, Debra Roter - JNCI Journal of the National Cancer Institute 2001 cited by 897

  15. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.

    Authors: Maurie Markman, Eric K. Rowinsky, Thomas B. Hakes, Bonnie Reichman, Wanda K. Jones, Joanne Lewis, Stephen C. Rubin, John P. Curtin, R. Barakat, M. Phillips - Journal of Clinical Oncology 1992 cited by 314

  16. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

    Authors: Prudence A. Francis, Eric K. Rowinsky, Juliane Schneider, T. Hakes, William J. Hoskins, Maurie Markman - Journal of Clinical Oncology 1995 cited by 196

  17. Primary ovarian cancer chemotherapy: current standards of care

    Authors: William P. McGuire, Maurie Markman - British Journal of Cancer 2003 cited by 168

  18. High-dose cisplatin with sodium thiosulfate protection.

    Authors: C E Pfeifle, Stephen B. Howell, R D Felthouse, T B Woliver, Paul A. Andrews, Maurie Markman, Michael P. Murphy - Journal of Clinical Oncology 1985 cited by 152

  19. Intravenous Vitamin C in the Supportive Care of Cancer Patients: A Review and Rational Approach

    Authors: Eiko Klimant, Hugh Wright, Deborah C. Rubin, Dugald Seely, Maurie Markman - Current Oncology 2018 cited by 103

  20. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients

    Authors: Marisa A. Navo, Anuradha Kunthur, Martina L. Badell, Larry Coffer, Maurie Markman, Jubilee Brown, Judith A. Smith - Gynecologic Oncology 2006 cited by 96

  21. Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial

    Authors: Maurie Markman, Pan Liu, Sharon P. Wilczynski, Bradley J. Monk, Larry J. Copeland, Ronald D. Alvarez, Caroline S. Jiang, David S. Alberts - Journal of Clinical Oncology 2003 cited by 458

  22. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study

    Authors: Maurie Markman, John A. Blessing, Stephen C. Rubin, Joseph P. Connor, Parviz Hanjani, Steven Waggoner - Gynecologic Oncology 2005 cited by 244

  23. Paclitaxel-Associated Hypersensitivity Reactions: Experience of the Gynecologic Oncology Program of the Cleveland Clinic Cancer Center

    Authors: Maurie Markman, Alexander Kennedy, Kenneth Webster, Barbara Kulp, Gertrude Peterson, Jerome L. Belinson - Journal of Clinical Oncology 2000 cited by 193

  24. Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer

    Authors: Siqing Fu, Wei Hu, Revathy B. Iyer, John J. Kavanagh, Robert L. Coleman, Charles F. Levenback, Anil K. Sood, Judith K. Wolf, David M. Gershenson, Maurie Markman, Bryan T. Hennessy, Razelle Kurzrock, Robert C. Bast - Cancer 2010 cited by 184